Does the pan-immune-inflammation value (PIV) predict long-term mortality better than other inflammation markers in patients with ST-segment elevation myocardial infarction?
The pan-immune-inflammation value (PIV) may serve as a superior prognostic biomarker for long-term mortality in patients following STEMI.
Our study reveals that PIV is a better predictor of mortality in STEMI patients. Prospective studies are needed to validate this biomarker.
Çaylı et al. (Tue,) studied this question.